News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News NICE approval for Keytruda a 'milestone' in lung cancer But drug will not be funded for longer than two years.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
